Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adaptive Open-label Study Evaluating the Safety and Efficacy of Autologous Non- Hematopoietic Peripheral Blood Stem Cells Therapy in COVID-19 Outbreak in Abu Dhabi, 2020 (SENTAD-COVID Study)

NCT04473170 is registered in ClinicalTrials.gov with Abu Dhabi Stem Cells Center as lead sponsor.

NCT NCT04473170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04473170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adaptive Open-label Study Evaluating the Safety and Efficacy of Autologous Non- Hematopoietic Peripheral Blood Stem Cells Therapy in COVID-19 Outbreak in Abu Dhabi, 2020 (SENTAD-COVID Study)
Lead sponsor
Abu Dhabi Stem Cells Center
Phase
Phase 1/2
Overall status
Completed
Start date
April 4, 2020
Completion date
July 14, 2020
Enrollment
146 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease 2019 (covid-19)